These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11. Gast CE, Basso LR, Bruzual I, Wong B. Antimicrob Agents Chemother; 2013 Nov; 57(11):5478-85. PubMed ID: 23979758 [Abstract] [Full Text] [Related]
3. Roles of Three Cryptococcus neoformans and Cryptococcus gattii Efflux Pump-Coding Genes in Response to Drug Treatment. Chang M, Sionov E, Khanal Lamichhane A, Kwon-Chung KJ, Chang YC. Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378705 [Abstract] [Full Text] [Related]
7. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J. Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877 [Abstract] [Full Text] [Related]
9. Multi-azole-resistant strains of Cryptococcus neoformans var. grubii isolated from a FLZ-resistant strain by culturing in medium containing voriconazole. Kano R, Okubo M, Hasegawa A, Kamata H. Med Mycol; 2017 Nov 01; 55(8):877-882. PubMed ID: 28927230 [Abstract] [Full Text] [Related]
13. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease. Nascimento E, Vitali LH, Kress MRVZ, Martinez R. Rev Inst Med Trop Sao Paulo; 2017 Nov 01; 59():e49. PubMed ID: 28793019 [Abstract] [Full Text] [Related]
15. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility. Lee GA, Arthur I, Merritt A, Leung M. Med Mycol; 2019 Nov 01; 57(8):1004-1010. PubMed ID: 30649538 [Abstract] [Full Text] [Related]
16. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil. Andrade-Silva L, Ferreira-Paim K, Mora DJ, Da Silva PR, Andrade AA, Araujo NE, Pedrosa AL, Silva-Vergara ML. Med Mycol; 2013 Aug 01; 51(6):635-40. PubMed ID: 23343452 [Abstract] [Full Text] [Related]
18. In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat. Sykes JE, Hodge G, Singapuri A, Yang ML, Gelli A, Thompson GR. Med Mycol; 2017 Jun 01; 55(4):396-401. PubMed ID: 28339594 [Abstract] [Full Text] [Related]
19. Heteroresistance of Cryptococcus gattii to fluconazole. Varma A, Kwon-Chung KJ. Antimicrob Agents Chemother; 2010 Jun 01; 54(6):2303-11. PubMed ID: 20385871 [Abstract] [Full Text] [Related]
20. From the environment to the host: How non-azole agrochemical exposure affects the antifungal susceptibility and virulence of Cryptococcus gattii. Bastos RW, Freitas GJC, Carneiro HCS, Oliveira LVN, Gouveia-Eufrasio L, Santos APN, Moyrand F, Maufrais C, Janbon G, Santos DA. Sci Total Environ; 2019 Sep 01; 681():516-523. PubMed ID: 31121401 [Abstract] [Full Text] [Related] Page: [Next] [New Search]